Cargando…

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

The clinical significance of ERBB2 amplification/overexpression in gastric cancer remains unclear. In this study, we evaluated the ERBB2 status in 463 gastric carcinomas using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH), and compared the findings with histopathological c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barros-Silva, J D, Leitão, D, Afonso, L, Vieira, J, Dinis-Ribeiro, M, Fragoso, M, Bento, M J, Santos, L, Ferreira, P, Rêgo, S, Brandão, C, Carneiro, F, Lopes, C, Schmitt, F, Teixeira, M R
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2658544/ https://www.ncbi.nlm.nih.gov/pubmed/19156142 http://dx.doi.org/10.1038/sj.bjc.6604885

Ejemplares similares

Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model
por: Hermes, M, et al.
Publicado: (2008)

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence
por: Pandya, K, et al.
Publicado: (2011)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours
por: Borriello, M, et al.
Publicado: (2011)

Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
por: Xu, W, et al.
Publicado: (2007)

Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma
por: Liles, J S, et al.
Publicado: (2011)

Regulation of focal adhesion turnover by ErbB signalling in invasive breast cancer cells
por: Xu, Y, et al.
Publicado: (2009)

Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours
por: Gelardi, T, et al.
Publicado: (2010)

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial
por: Provenzano, E, et al.
Publicado: (2013)

The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice
por: Li, Y, et al.
Publicado: (2008)

Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct
por: Roth, A, et al.
Publicado: (2005)

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
por: Fujita, T, et al.
Publicado: (2006)

Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
por: Takahashi, Naoki, et al.
Publicado: (2016)

Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells
por: Pichot, C S, et al.
Publicado: (2009)

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
por: Agarwal, S, et al.
Publicado: (2009)

Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells
por: Armstrong, J L, et al.
Publicado: (2005)

Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57
por: Corazzari, M, et al.
Publicado: (2007)

A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia
por: Gallagher, W M, et al.
Publicado: (2005)

Surgery combined with controlled-release doxorubicin silk films as a treatment strategy in an orthotopic neuroblastoma mouse model
por: Chiu, B, et al.
Publicado: (2014)

Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224)
por: Doñate, F, et al.
Publicado: (2008)

Downregulated NM23-H1 expression is associated with intracranial invasion of nasopharyngeal carcinoma
por: Liu, S J, et al.
Publicado: (2008)

Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer
por: Weickhardt, A J, et al.
Publicado: (2015)

Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells
por: Roberts, D L, et al.
Publicado: (2009)

Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours
por: Mendoza, J, et al.
Publicado: (2013)

Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab
por: Gualberto, A, et al.
Publicado: (2011)

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer
por: Konecny, G E, et al.
Publicado: (2009)

Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen
por: Conaghan, P J, et al.
Publicado: (2008)

Engineering and characterisation of chimeric monoclonal antibody 806 (ch806) for targeted immunotherapy of tumours expressing de2-7 EGFR or amplified EGFR
por: Panousis, C, et al.
Publicado: (2005)

Elevated dietary linoleic acid increases gastric carcinoma cell invasion and metastasis in mice
por: Matsuoka, T, et al.
Publicado: (2010)

Stat3 activation in human endometrial and cervical cancers
por: Chen, C-L, et al.
Publicado: (2007)

Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide
por: Chang, J, et al.
Publicado: (2012)

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells
por: Lin, Y, et al.
Publicado: (2012)

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
por: Lamont, F R, et al.
Publicado: (2011)

Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease
por: Kang, B H, et al.
Publicado: (2011)

[(18)F]FDG and [(18)F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study
por: Direcks, W G E, et al.
Publicado: (2008)

Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects
por: Ferreira, A K, et al.
Publicado: (2013)

The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance
por: Toner, A P, et al.
Publicado: (2013)

Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation
por: de Plater, L, et al.
Publicado: (2010)

Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
por: Pedretti, M, et al.
Publicado: (2010)

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
por: Kaymakcalan, M D, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_nbvji5adeindamvov86mfras1n